British-based oncology R&D charity Cancer Research UK will inject £45 million ($63 million) across its clinical trial network in the U.K.
Those participating in a startup support program will gain immediate access to Science Exchange’s outsourced R&D platform.
The careful optimization of tumor-bearing humanized models leads to highly useful preclinical immuno-oncology platforms for accelerated immunotherapy…
The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.
Charles River Laboratories snatches up nonclinical CRO MPI Research for $800 million in cash.
Preclinical CRO Sinclair Research has carved out a new role for G. Alex Wakefield as he becomes its vice president of research and operations.
HemaCare will evaluate human PBMCs in advance for use in Charles River's immunodeficient mouse kits.
Abcam and Molecular Devices combine their technologies in a series of high-sensitivity fluorescent enzyme-linked immunosorbent assay kits.
Charles River will perform HTS programs for its clients using AstraZeneca’s state-of-the-art HTS facility.
A 14% hit rate for drug approvals coming out of clinical trials might not sound great, but MIT researchers say this is much higher than they thought.
This is the first time a research manufacturer has enabled on its website direct ordering of services provided by those using its products.